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Clear cell renal cell carcinoma (CC-RCC) is a highly vascularised tumour and is therefore an attractive disease to study angiogenesis
and to test novel angiogenesis inhibitors in early clinical development. Endothelial cell proliferation plays a pivotal role in the process
of angiogenesis. The aim of this study was to compare angiogenesis parameters in low nuclear grade (n¼87) vs high nuclear grade
CC-RCC (n¼63). A panel of antibodies was used for immunohistochemistry: CD34/Ki-67, carbonic anhydrase IX, hypoxia-inducible
factor-1a (HIF-1a) and vascular endothelial growth factor (VEGF). Vessel density (MVD – microvessel density), endothelial cell
proliferation fraction (ECP%) and tumour cell proliferation fraction (TCP%) were assessed. mRNA expression levels of angiogenesis
stimulators and inhibitors were determined by quantitative RT–PCR. High-grade CC-RCC showed a higher ECP% (P¼0.049), a
higher TCP% (P¼0.009), a higher VEGF protein expression (Po0.001), a lower MVD (Po 0.001) and a lower HIF-1a protein
expression (P¼0.002) than low-grade CC-RCC. Growth factor mRNA expression analyses revealed a higher expression of
angiopoietin 2 in low-grade CC-RCC. Microvessel density and ECP% were inversely correlated (Rho¼ 0.26, P¼0.001). Because of
the imperfect association of nuclear grade and ECP% or MVD, CC-RCC was also grouped based on low/high MVD and ECP%. This
analysis revealed a higher expression of vessel maturation and stabilisation factors (placental growth factor, PDGFB1, angiopoietin 1)
in CC-RCC with high MVD, a group of CC-RCC highly enriched in low nuclear grade CC-RCC, with low ECP%. Our results suggest
heterogeneity in angiogenic activity and vessel maturation of CC-RCC, to a large extent linked to nuclear grade, and, with probable
therapeutic implications.
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Clear cell renal cell carcinoma (CC-RCC) is the most common
carcinoma of the renal tubular epithelium accounting for
approximately 75% of cases in surgical series (Kovacs et al,
1997). Aberrations of the von Hippel-Lindau (VHL) tumour
suppressor gene have been shown to be an early and distinct event
in the development of CC-RCC (Kaelin, 2004). In up to 70% of CC-
RCC, somatic VHL gene inactivation occurs (Clifford et al, 1998).
The VHL gene product (pVHL) binds the hypoxia-inducible factor
1a (HIF-1a) in normoxic cells. Lack of VHL protein leads to
stabilisation of HIF-1a, a state that is normally seen only in hypoxic
cells. The increased levels of HIF-1a in CC-RCC (Wiesener et al,
2001) are thus mainly caused by genetic alterations of the VHL gene
in addition to or despite stimulation through hypoxia. Stabilisation
of HIF-1a activates a cascade of pathways, which include
angiogenesis, glycolysis, proliferation and alterations in micro-
environmental pH (carbonic anhydrase IX (CAIX)) (Semenza,
1999). Overexpression of angiogenic factors due to HIF-1a
upregulation can explain the hypervascular nature of CC-RCC.
Tumour angiogenesis is a complex process that is regulated by a
balance between pro-angiogenic and anti-angiogenic factors. This
balance is influenced by tumour cells and the tumour’s micro-
environment (Carmeliet and Jain, 2000; Griffioen and Molema,
2000). The main player in angiogenesis is the endothelial cell (EC),
and numerous activators of EC proliferation and migration have
been described. Most of these activators are receptor kinase
ligands, such as vascular endothelial growth factor (VEGF),
fibroblast growth factor (FGF), platelet-derived growth factor
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s(PDGF) and epidermal growth factor (EGF), but they can also be of
different origin, such as lysophosphatic acid or interleukin-8 (IL8),
tumour necrosis factor-a (TNF-a) (Konig et al, 1999; Ruoslahti,
2002; Bergers and Benjamin, 2003). Naturally occurring angiogenic
inhibitors include statins (e.g. endostatin, angiostatin), thrombo-
spondin 1 (TSP1) and platelet-derived factor 4 (PF4).
Clear cell renal cell carcinoma has an unpredictable course. The
most widely used tumour-related prognostic factors in RCC
include stage, Fuhrman nuclear grade and histological type (Gelb,
1997). Additional markers, still under investigation, are cellular
proliferation, apoptosis and angiogenesis, among others.
As the highly vascularised phenotype of CC-RCC suggests that
angiogenesis is integral to its pathogenesis, the aim of our study
was to compare the angiogenic potential of low-grade CC-RCC
(Fuhrman grade 1 and 2) with high-grade CC-RCC (Fuhrman
grade 3 and 4). To that end, EC proliferation, a measure of ongoing
angiogenesis, was immunohistochemically assessed and correlated
with vessel density (MVD – microvessel density), tumour cell
proliferation, HIF-1a, VEGF and CAIX expression. Additionally,
the mRNA expression levels of VEGF (-A/B/C), bFGF, placental
growth factor (PLGF), angiopoietin 1 (ANG1), angiopoietin 2
(ANG2), PDGFB1, EGF, TNF-a, transforming growth factor-a
(TGF-a), transforming growth factor-b (TGF-b), IL8, PF4, TSP1,
vascular endothelial receptors 1 and 2 (VEGFR1 and VEGFR2)
were determined within low- and high-grade CC-RCC and
correlated with immunohistochemical (IHC) angiogenesis data.
MATERIALS AND METHODS
Patients and tissue specimens
Tumour samples of 150 patients with CC-RCC, treated with radical
or partial nephrectomy were collected retrospectively. The samples
were derived from the archives of the Departments of Histopathol-
ogy of the University Hospitals of Leuven and Maastricht. None of
the patients received any cancer-related therapy before surgery.
The original histological slides, stained with haematoxylin and
eosin, were reviewed to confirm nuclear Fuhrman grading. All
patients were evaluated postoperatively at regular intervals by
means of physical examination, chest X-ray, abdominal computed
tomography or ultrasound (median follow-up 64 months, range
1–153 months). When indicated, a bone scan was performed. The
clinicopathological data of the study population are summarised in
Table 1.
Quantification of MVD, endothelial cell proliferation
fraction and tumour cell proliferation fraction
Serial sections of 4mm were made from the paraffin-embedded
kidney tumours. A CD34/Ki67 double-stain procedure was
performed on an automated IHC staining system (Dako Auto-
stainer; Dako, Glostru ¨p, Denmark), as described before (Van den
Eynden et al, 2005). This technique is used to simultaneously stain
ECs (cytoplasmic CD34) and proliferating cells (nuclear
Ki-67). Anti-Ki-67 (clone MIB-1, dilution 1/150, Dako, Glo ¨strup,
Denmark) antibody binding was visualised with secondary anti-
body-labelled polymers containing peroxidase with Diaminobenzi-
dine (DAB) as a substrate. For detection of anti-CD34 (clone QBEnd/
10, dilution 1/50, Dako) binding, secondary antibody labelled with
an alkaline group and fast red substrate were used. One section was
analysed per tumour. For assessment of the vascular density within a
tumour section, one hotspot (most vascularised microscopic field)
was selected and four areas were chosen randomly. Vessel counts
were carried out at  200 magnification using an optical grid. The
presence of a vascular lumen was not necessary to identify a
microvessel. Microvessel density was expressed as vessels per mm
2.
Next, a total number of approximately 500 intratumoural ECs and
500 tumour cells were evaluated on consecutive fields at a  400
magnification and the fractions of proliferating ECs and tumour
cells were assessed. Endothelial cell proliferation fraction (ECP%)
and tumour cell proliferation (TCP%) were calculated according to
the following formulas: ECP%¼(the number of ECs with Ki67-
stained nuclei/total number of ECs evaluated) 100; TCP%¼(the
number of tumour cells with Ki67-stained nuclei/total number of
tumour cells evaluated) 100. Furthermore, in a subgroup of fifteen
grade 1 and fifteen grade 4 CC-RCC vessel area was determined by
means of Leica Qwin morphometry system (Version 3.2.1, Leica
Cambridge, UK).
Assessment of HIF-1a, CA IX and VEGF
Carbonic anhydrase IX IHC staining was automated using the
Dako Autostainer (Dako). Primary antibody anti-CAIX (Rabbit
polyclonal, diluted 1/2000, Novus Biologicals, Littleton, CO, USA)
was incubated for 60min at room temperature. Antibody binding
was visualised with the ChemMate Envisionþdetection system
(Dako). Semiquantitative analysis of CAIX expression was
performed as described before (Chia et al, 2001; Chakrabarti
et al, 2004; Van den Eynden et al, 2005). In short, a score of
0–3 for intensity of staining was given (0: no staining, 1: weak
staining, 2: moderate staining, 3: strong staining). The percentage
of immunostained tumour cells was estimated. The product
(intensity score the percentage of immunoreactive tumour cells)
yielded a final score of 0–300.
The HIF-1a IHC staining was carried out manually, as described
elsewhere (Van den Eynden et al, 2005), using an anti-HIF-1a
primary antibody (Clone 54, diluted 1/500, BD Pharmingen,
Franklin Lake, NJ, USA). For HIF-1a expression analysis, only
cells with completely and darkly stained nuclei were scored as
positive. The fraction of HIF-1a-positive tumour cells was
estimated.
The VEGF IHC staining was performed with Rabbit polyclonal
antisera to VEGF reacting with VEGF A isoforms 165 and 121
(Peprotech Inc., Rocky Hill, New York, NY, USA) at a 1/50 dilution.
After rinsing with TBS, the slides were blocked for aspecific
antibody binding with 1% normal goat serum in TBS for 30min,
followed by incubation with the primary rabbit antihuman VEGF-A
antibody. After washing with TBS, the slides were incubated with
Powervision poly-HRP goat anti-mouse/rabbit/rat (Immunologic/
Klinpath,NL,DPVO-55hrp) for 30min. Subsequently, an incubation
was performed with avidine–biotin complex HRP (Dako) and
developed with DAB (Sigma, Zwijndrecht, The Netherlands) for
10min. The slides were counterstained with haematoxylin (Merck,
Table 1 Clinical and histopathological characteristics
Clinicopathological data
(N¼150)
Gender male/female 99/51 (66/34%)
Age (years) 66.6 (712.1s.d.)
Mean tumour diameter (cm) 6.36 (73.45s.d.)
Median tumour diameter (cm) 6.00 (0.7–20.0 range)
Fuhrman grade
1 15 (10.0%)
2 72 (48.0%)
3 46 (30.7%)
4 17 (11.3%)
Tumour status
a
T1 82 (54.7%)
T2 24 (16.0%)
T3 42 (28.0)
T4 2 (1.3%)
Lymph node status
a
14
21 1
aT and N status were assigned according to the TNM classification of the
International Union Against Cancer 2002.
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sDarmst, Germany) and mounted for lightmicroscopical evaluation.
As negative control, we used slides with normal kidney and
RCC tissue, without application of the primary antibody. The
staining was semiquantitatively assessed according to a 4-point
grading scale: 0 absence of tumour staining, 1þ membrane
staining tumour cells, 2þ strong membrane staining and
cytoplasmic staining of o50% of the tumour cells and 3þ strong
cytoplasmic staining in 450% of all tumour cells.
RNA isolation, cDNA synthesis and quantitative PCR
analysis
From 33 frozen tumour tissues and 16 normal renal tissues,
total RNA was isolated from 10 cryosections (20mm) with the
RNeasy mini kit (Qiagen Benelux B.V., Venlo, The Netherlands)
according to the supplier’s protocol. Possible genomic
DNA contamination was removed by on column DNaseI treatment
for 20min at room temperature. Concentration and quality of the
RNA was analysed on the NanoDrop ND-1000 (Nanodrop
Technologies Inc., Wilmington, USA) and by agarose gel electro-
phoresis, respectively. A total amount of 100ng total RNA was
used for cDNA synthesis with the iScript cDNA synthesis kit (Bio-
Rad Laboratories B.V., Veenendaal, The Netherlands) according to
the supplier’s protocol. Quantitative PCR was performed with the
iCycler (Bio-Rad) in a total volume of 25ml on 30ng cDNA with the
iQ SYBR Green Supermix (Bio-Rad) and 400nM forward and
reverse primer. The primers used for this study have been
described before or were designed and validated as described
previously (Thijssen et al, 2004). Primers were synthesised by
Eurogentec and targeted against cyclophilinA, b-actin, 18S rRNA,
VEGF (VEGF-A), VEGF-B, VEGF-C, bFGF, PLGF, ANG1, ANG2,
EGF, PDGFB1, TNF-a, IL8, PF4, TGF-a, TGF-b, TSP-1, VEGFR1
and VEGFR2.
Statistical analysis
Statistical analysis was performed using the SPSS 12.0. software
package. A P-value p0.05 was statistically significant, a 0.05o
P-value p0.1 was considered a trend toward statistical signifi-
cance. Normality was tested with a Kolmogorov–Smirnov test
assuming normality of data if PX0.2. If continuous data were
normally distributed, correlations were analysed with Pearson’s
correlation statistics, if not, with Spearman’s correlation statistics.
In case of normal distribution in all subgroups, equality of means
was tested with a Student’s t-test. If data were not normally
distributed, equality of medians was tested with a Mann–Whitney
U-test. For analysing correlations between categorical variables
(e.g. high/low ecp%, high/low mvd, high/low grade), a w
2 test or,
when the assumptions for the w
2 test were not met, the Fisher’s
exact test was used.
RESULTS
Angiogenesis in low-grade CC-RCC compared with high-
grade CC-RCC
Median MVD was 181.1 (range 27.6–481.8), median ECP% was
0.7% (range 0–13.2%) and median TCP% was 3.8% (range 0–
46.0%). Carbonic anhydrase IX and HIF-1a were expressed in 97
and 88% of all tumours, respectively. Vascular endothelial growth
factor immunostaining was present in all CC-RCC and was
observed mainly in tumour cells and in endothelial cells of
intratumoural vessels (Figure 1). Vascular endothelial growth
factor immunostaining was graded 1þ in 59 tumours (39.3%),
2þ in 66 tumours (44%) and 3þ in 25 tumours (16.7%). Vascular
endothelial growth factor protein expression was inversely related
to MVD (Rho¼ 0.42, Po0.001). There was an inverse correlation
between MVD and Fuhrman grade (Rho¼ 0.40, Po0.001).
Endothelial cell proliferation fraction had a moderate positive
correlation with Fuhrman grade (Rho¼0.17, P¼0.029). Micro-
vessel density and ECP% were inversely correlated (Rho¼ 0.26,
P¼0.001).
Based on these results, the group of CC-RCC was split into two
groups: high grade (Fuhrman grade 3 and 4) and low grade
(Fuhrman grade 1 and 2). Table 2 shows the differences in
angiogenesis parameters and hypoxia-related parameters between
both sub-populations. High-grade CC-RCC had higher ECP%
(Figure 2), higher TCP%, larger vessel area and higher VEGF
protein expression. In contrast, MVD, CAIX protein expression
and HIF-1a protein expression were lower in high-grade tumours.
Tables 3 and 4 illustrate the expression of angiogenic growth
factors/inhibitors in CC-RCC and normal renal tissue. In renal
tumour tissues, there was a significant overexpression of VEGF
(Po0.001), VEGF-B (P¼0.004), VEGF-C (P¼0.032), PLGF
(Po0.001), ANG2 (Po0.001), PDGFB1 (P¼0.009) and TGF-a
(Po0.001) compared to normal renal tissue (Table 3). In contrast,
renal cell carcinoma expressed less bFGF (Po0.001) and EGF
(Po0.001) than normal renal tissue.
When comparing the PCR data of the angiogenic growth factors
in low- and high-grade tumours (Table 4), only a significant
difference could be found in ANG2 expression, which was higher
in low-grade tumours (P¼0.035). Low-grade tumours also
expressed more VEGFR1 and 2 than high-grade CC-RCC
(P¼0.023 and P¼0.004, respectively).
mRNA expression of angiogenesis-related factors in
CC-RCC grouped according to median MVD and median
ECP%
Because of the imperfect association of nuclear grade and ECP% or
MVD (Figure 3) and to get more insight in the biology of both
vascular patterns related to the inverse association of MVD and
ECP%, CC-RCC were also grouped based on low/high MVD (cutoff
median MVD of 181) and high/low ECP% (cutoff median ECP% of
0.7%). In the CC-RCC with high MVD, there was a higher mRNA
expression of VEGF (P¼0.007), ANG2 (Po0.001), PLGF
(P¼0.007) and PDGFB1 (P¼0.001). There was also more mRNA
expression of VEGFR1 and VEGFR2 in the high MVD group
(P¼0.001 and Po0.001). A higher expression of ANG1 was found
in tumours with low ECP% (P¼0.008).
DISCUSSION
The interest of our study was to compare angiogenesis parameters
in low-grade vs high-grade CC-RCC. In earlier studies, MVD
was used as a parameter for angiogenesis in RCC and evaluated as
a possible prognostic marker, however leading to conflicting
results (Gelb et al, 1997; Nativ et al, 1998; Rioux-Leclercq et al,
2001; Sabo et al, 2001). To our knowledge, this is the first study in
which the fraction of proliferating ECs (ECP%) is investigated
within RCC.
High-grade CC-RCCs were characterised by a high ECP%, which
correlated strongly with TCP%. In spite of the higher ECP% in
high-grade CC-RCC than the low-grade subgroup, MVD was lower
in high-grade CC-RCC. These results suggest that ECP% is a better
indicator for ongoing angiogenesis in CC-RCC than MVD. Vessel
density reflects intercapillary distance, which is determined by
angiogenic factors (stimulators and inhibitors), as well as
nonangiogenic factors, such as oxygen and nutrient consumption
rates of tumour cells (Hlatky et al, 2002). Tumour progression is
associated with a gradual reduction in the intrinsic propensity of
cancer cells to undergo apoptosis under a variety of noxious
conditions (Bedi et al, 1995). Cumulative effects of genetic
alterations, by means of altered expression of tumour suppressor
genes (PTEN, p53 and VHL) and oncogenes (ras,src) could affect
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to hypoxia (Semenza, 2000). In patients with localised RCC,
p53 appeared to be an independent predictor of tumour
progression. (Shvarts et al, 2005). As a relative decrease of
vascular dependence of cancer cells is associated with features of
increased malignancy (Carmeliet et al, 1998; Yu et al, 2001),
tolerance of hypoxic conditions can explain why high-grade renal
tumours can afford an increased intercapillary distance in
comparison with low-grade RCC.
In our study, 88% of all CC-RCC showed activation of HIF1-a
throughout the whole tumour section, independently of the
presence of necrosis. This is consistent with the fact that in 70%
of CC-RCC there is a constitutive activation of HIF, through VHL
inactivation (Clifford et al, 1998). Nevertheless differences in HIF-
1a expression were seen between low- and high-grade CC-RCC.
The lower HIF-1a expression in high-grade CC-RCC could possibly
be explained by a progressive switch to HIF-2a response during
tumour progression. An earlier report stated that normal renal
epithelium in vivo activates HIF-1a in response to hypoxia and
VHL loss with little or no HIF-2a (Rosenberger et al, 2002).
Hypoxia-inducible factor-2a appears to become progressively
more evident than HIF-1a in foci of renal dysplasia, cyst formation
and frank tumours (Mandriota et al, 2002). As HIF-1a and HIF-2a
have contrasting properties (Raval et al, 2005), a possible switch to
HIF-2a could increase the likelihood to proliferation and survival,
during tumour evolution.
A B
C
E
G
D
F
H
Figure 1 Overview of the IHC stainings used, in low-grade (left: A, C, E, G) and high-grade (right: B, D, F, H) CC-RCC. (A and B) CD34/Ki-67 IHC
double-staining. Black arrows in inset show proliferating Ki-67 positive (brown nucleus) ECs (red cytoplasm). (C and D) Morphometrical analyses showing an
increased vessel area (grey) in high-grade CC-RCC. (E and F) Membranous CAIX staining and nuclear HIF-1a staining (inset) of tumour cells. Although
no significant difference was found between low- and high-grade tumours for CAIX expression, there was more HIF-1a expression in low-grade CC-RCC.
(G and H) Predominantly membranous VEGF staining in tumour cells of low-grade RCC (G), in contrast with dense cytoplasmic intratumoural VEGF
staining in high-grade RCC (H). Insets also illustrate VEGF immunoreactivity of the intratumoural vessels.
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levels between low- and high-grade CC-RCCs, revealed only a
significant difference in ANG2 expression, which was significantly
higher in the low-grade CC-RCC group. Angiopoietin 2 expression
is often induced in endothelia undergoing active remodelling or
regression and is upregulated by hypoxia and several growth
factors, including VEGF (Oh et al, 1999; Mandriota et al, 2000).
Administration of inhibitors of ANG2 to tumour-bearing mice has
been reported to result in delayed tumour growth and reduced EC
proliferation. Therefore, inhibitors of ANG2 may be candidates for
clinical development (Oliner et al, 2004).
In our study, there is a discrepancy between the IHC VEGF data
and mRNA VEGF expression. Low-grade CC-RCC with high MVD
are characterised by a lower VEGF protein expression and higher
mRNA VEGF expression than high-grade CC-RCC with low MVD.
This can be explained by the fact that in the IHC VEGF staining we
only scored cytoplasmic VEGF positivity in tumour cells, whereas
mRNA VEGF expression also includes VEGF in stroma and at the
surface of ECs. In our case, CC-RCC with high MVD showed VEGF
positive staining of the numerous tumoural vessels (Figure 1).
Within our group of 150 CC-RCCs, the association of MVD and
ECP% with nuclear grade was however imperfect. Therefore, to get
more insight in angiogenesis biology, we compared the mRNA
expression levels of angiogenesis-related factors between two
subgroups, based on MVD and ECP%, respectively, and leaving
Fuhrman grade out of account. Clear cell renal cell carcinoma with
Table 2 Immunohistochemical and morphometric results of angiogenesis parameters in low-grade vs high-grade CC-RCC
MVD
a Hotspot ECP% TCP% CAIX HIF Vessel area
b VEGF
c
Low-grade RCC Min 44.220 52.030 0% 0% 0 0% 54.99 1: 57.5%
Median 233.870 297.865 0.6% 2.5% 285 40% 122.80 2: 39.1%
Max 481.790 741.420 5.4% 30.9% 300 100% 229.83 3: 3.4%
High-grade RCC Min 27.580 49.430 0% 0% 0 0% 79.66 1: 14.3%
Median 150.880 250.520 1% 5% 240 15% 148.44 2: 50.8%
Max 429.760 590.530 13.2% 46% 300 95% 588.30 3: 34.9%
P-value o0.001 o0.001 0.049 0.009 0.262 0.002 0.017 o0.001
Abbreviations: CAIX¼carbonic anhydrase IX; CC-RCC¼clear cell renal cell carcinoma; ECP%¼endothelial cell proliferation fraction; HIF¼hypoxia-inducible factor;
MVD¼microvessel density; RCC¼renal cell carcinoma; TCP%¼tumour cell proliferation fraction; VEGF¼vascular endothelial growth factor. P-value: comparison between
low-grade and high-grade RCC (Mann–Whitney).
aMVD expressed as vessels per mm
2.
bVessel area expressed as mm
2.
cFor VEGF, the percentage of each of the scores is
represented.
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Figure 2 Microvessel density and ECP% according to tumour grade. ECP%: endothelial cell proliferation fraction (%). MVD: microvessel density (vessels
per mm
2).
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sTable 4 Results of PCR quantification of angiogenesis-related genes in low-grade vs high-grade CC-RCC
VEGFA VEGFB VEGFC bFGF PLGF ANG1 ANG2 EGF PDGFB1 TNFa
Low-grade RCC
N 2 32 32 3 2 3 2 32 3 2 3 2 3 2 32 3
Min 0.094 0.008 0.001 0.002 0.009 0.001 0.012 0.000 0.009 0.000
Median 1.187 0.044 0.008 0.045 0.130 0.009 0.053 0.001 0.048 0.002
Max 4.326 0.209 0.073 0.250 1.945 0.098 0.123 0.034 0.220 0.006
High-grade RCC
N 1 01 01 0 1 0 1 01 0 1 0 1 0 1 01 0
Min 0.091 0.008 0.003 0.009 0.007 0.000 0.006 0.000 0.008 0.000
Median 0.953 0.028 0.008 0.034 0.030 0.004 0.027 0.000 0.017 0.002
Max 4.060 0.119 0.049 0.251 0.360 0.028 0.063 0.042 0.167 0.005
P-value 0.597 0.208 0.968 0.393 0.113 0.464 0.035 0.122 0.167 0.903
IL8 TGFa TGFb TSP1 PF4 VEGFR1 VEGFR2
Low-grade RCC
N 2 32 32 3 2 3 2 32 3 2 3
Min 0.000 0.000 0.041 0.007 0.000 0.001 0.006
Median 0.007 0.038 0.239 0.181 0.000 0.019 0.041
Max 0.045 0.169 1.148 0.757 0.000 0.052 0.205
High-grade RCC
N 1 01 01 0 1 0 1 01 0 1 0
Min 0.000 0.000 0.043 0.030 0.000 0.000 0.002
Median 0.006 0.038 0.391 0.258 0.000 0.007 0.010
Max 0.110 0.113 0.972 2.158 0.000 0.034 0.042
P-value 0.839 0.871 0.371 0.776 0.371 0.023 0.004
Abbreviations: ANG1¼angiopoietin 1; ANG2¼angiopoietin 2; bFGF¼basic fibroblast growth factor; CC-RCC¼clear cell renal cell carcinoma; EGF¼epidermal growth
factor; IL8¼interleukin-8; PDGFB1¼platelet-derived growth factor-B1; PF4¼platelet-derived factor 4; PLGF; placental growth factor; RCC¼renal cell carcinoma; TGF-
a¼transforming growth factor-a; TNF-a¼tumour necrosis factor-a; TSP1¼thrombospondin 1; VEGFA¼vascular endothelial growth factor-A; VEGFB¼vascular endothelial
growth factor-B; VEGFC¼vascular endothelial growth factor-C. Expression values are shown as 2
 D. P-value: comparison between low-grade and high-grade RCC (Mann–
Whitney).
Table 3 Results of PCR quantification of angiogenesis-related genes in normal renal tissue versus CC-RCC
VEGFA VEGFB VEGFC BFGF PLGF ANG1 ANG2 EGF PDGFB1 TNFa
Normal
N 1 61 61 61 61 61 6 1 61 6 1 61 6
Min 0.055 0.012 0.003 0.092 0.002 0.007 0.001 0.004 0.009 0.000
Median 0.124 0.020 0.004 0.882 0.006 0.010 0.003 0.048 0.018 0.001
Max 0.334 0.026 0.014 1.717 0.011 0.053 0.0138 0.268 0.057 0.011
RCC
N 3 33 33 33 33 33 3 3 33 3 3 33 3
Min 0.091 0.008 0.001 0.002 0.007 0.000 0.006 0.000 0.008 0.000
Median 1.187 0.035 0.008 0.045 0.114 0.007 0.045 0.001 0.037 0.002
Max 4.326 0.209 0.073 0.251 1.945 0.098 0.123 0.042 0.220 0.006
P-value o0.001 0.004 0.032 o0.001 o0.001 0.486 o0.001 o0.001 0.009 0.703
IL8 TGFa TGFb TSP1 PF4 VEGFR1 VEGFR2
Normal
N 1 61 61 61 61 61 6 1 6
Min 0.001 0.004 0.023 0.003 0.000 0.001 0.007
Median 0.003 0.009 0.241 0.158 0.000 0.008 0.016
Max 0.037 0.015 1.515 0.489 0.000 0.018 0.035
RCC
N 3 33 33 33 33 33 3 3 3
Min 0.000 0.000 0.041 0.007 0.000 0.000 0.002
Median 0.007 0.038 0.260 0.227 0.000 0.012 0.030
Max 0.110 0.169 1.148 2.158 0.000 0.052 0.205
P value 0.875 o0.001 0.745 0.686 0.884 0.035 0.121
Abbreviations: ANG1¼angiopoietin 1; ANG2¼angiopoietin 2; BFGF¼basic fibroblast growth factor; CC-RCC¼clear cell renal cell carcinoma; EGF¼epidermal growth
factor; PDGFB1¼platelet-derived growth factor-B1; PF4¼platelet-derived factor 4; PLGF; placental growth factor; RCC¼renal cell carcinoma; TNF¼tumour necrosis factor;
TSP1¼thrombospondin 1; VEGFA¼vascular endothelial growth factor-A; VEGFB¼vascular endothelial growth factor-B; VEGFC¼vascular endothelial growth factor-C.
Expression values are shown as 2
 DCt. P-value: comparison between normal and RCC (Mann–Whitney).
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shigh MVD revealed a significant higher PLGF and PDGFB1
expression. Placental growth factor, a VEGF-related factor,
contributes to tumour angiogenesis by providing increased
survival function to ECs (Adini et al, 2002). PDGFB is required
for recruitment of pericytes and maturation of microvasculature
(Lindahl et al, 1997). Furthermore, tumours with low ECP%,
revealed a higher ANG1 expression, which competes with ANG2
for binding of Tie-2 receptor. Angiopoietin 1 promotes EC
sprouting and is essential for maturation and stabilisation of the
developing vascularisation (Papapetropoulos et al, 1999; Distler
et al, 2003). These findings suggest that CC-RCC with high MVD
and low ECP% may have a more stabilised and mature vasculature
than their counterpart. Our finding is concordant with a recent
study, which described differentiated and undifferentiated types of
blood vessels in CC-RCC (Yao et al, 2007). They found that an
increased density of undifferentiated vessels significantly corre-
lated with higher pathological grades and shorter patient survival.
As immature vasculature has been shown to be more vulnerable
for therapeutic targeting (Feron, 2004), a better response to anti-
angiogenic drugs might be expected in the high-grade CC-RCC.
Selection of resistant tumour cells can however still occur (Yu et al,
2002). On the other hand, anti-VEGF treatment probably has direct
effects on tumour cells of CC-RCC because these cells express KDR
that is phosphorylated, independent of grade (Fox et al, 2004).
In summary, the results of this study suggest that high-grade
CC-RCC have a different angiogenic pattern than low-grade CC-
RCC, with more EC proliferation in the former tumours, but lower
MVD, with larger and more immature vessels. These differences in
angiogenesis biology might have impact on the effects of anti-
angiogenic or anti-VEGF treatment of CC-RCC.
REFERENCES
Adini A, Kornaga T, Firoozbakht F, Benjamin LE (2002) Placental growth
factor is a survival factor for tumor endothelial cells and macrophages.
Cancer Res 62: 2749–2752
Bedi A, Pasricha PJ, Akhtar AJ, Barber JP, Bedi GC, Giardiello FM,
Zehnbauer BA, Hamilton SR, Jones RJ (1995) Inhibition of apoptosis
during development of colorectal cancer. Cancer Res 55: 1811–1816
Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch.
Nat Rev Cancer 3: 401–410
Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases.
Nature 407: 249–257
Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin
M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P,
Moons L, Jain RK, Collen D, Keshert E (1998) Role of HIF-1alpha in
hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis.
Nature 394: 485–490
Chakrabarti J, Turley H, Campo L, Han C, Harris AL, Gatter KC, Fox SB
(2004) The transcription factor DEC1 (stra13, SHARP2) is associated
with the hypoxic response and high tumour grade in human breast
cancers. Br J Cancer 91: 954–958
Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC,
Ratcliffe P, Harris AL (2001) Prognostic significance of a novel hypoxia-
regulated marker, carbonic anhydrase IX, in invasive breast carcinoma.
J Clin Oncol 19: 3660–3668
Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER (1998) Inactivation
of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic
losses at chromosome arm 3p in primary renal cell carcinoma: evidence
MVD median (181)
ECP% high-MVD low
ECP% low-MVD low
Grade
Low
Low
High
43
<0.001
<0.001
0.069
19
26
37
28
11
High grade
ECP% median (0.7%)
0
0
15
10
7
6
5
4
3
2
1
50 100 150 200 250 300 350 400 450 500 550
Low grade
MVD (number of vessels per mm2)
E
C
P
 
%
37
19
38
49
56
31
High
High
P-value Low
MVD
ECP%
Figure 3 Scatter plot of low-grade (open dots) and high-grade (filled dots) CC-RCC according to median MVD and median ECP%. Tumours with low
ECP% and high MVD are mainly low-grade CC-RCC. Tumours with high ECP% and low MVD are mainly high-grade CC-RCC.
Angiogenesis in renal cell carcinoma
MM Baldewijns et al
1894
British Journal of Cancer (2007) 96(12), 1888–1895 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sfor a VHL-independent pathway in clear cell renal tumourigenesis. Genes
Chromosomes Cancer 22: 200–209
Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O (2003)
Angiogenic and angiostatic factors in the molecular control of
angiogenesis. Q J Nucl Med 47: 149–161
Feron O (2004) Targeting the tumor vascular compartment to improve
conventional cancer therapy. Trends Pharmacol Sci 25: 536–542
Fox SB, Turley H, Cheale M, Blazquez C, Roberts H, James N, Cook N,
Harris A, Gatter K (2004) Phosphorylated KDR is expressed in the
neoplastic and stromal elements of human renal tumours and shuttles
from cell membrane to nucleus. J Pathol 202: 313–320
Gelb AB (1997) Renal cell carcinoma: current prognostic factors. Union
Internationale Contre le Cancer (UICC) and the American Joint
Committee on Cancer (AJCC). Cancer 80: 981–986
Gelb AB, Sudilovsky D, Wu CD, Weiss LM, Medeiros LJ (1997) Appraisal of
intratumoral microvessel density, MIB-1 score, DNA content, and p53
protein expression as prognostic indicators in patients with locally
confined renal cell carcinoma. Cancer 80: 1768–1775
Griffioen AW, Molema G (2000) Angiogenesis: potentials for pharmaco-
logic intervention in the treatment of cancer, cardiovascular diseases,
and chronic inflammation. Pharmacol Rev 52: 237–268
Hlatky L, Hahnfeldt P, Folkman J (2002) Clinical application of
antiangiogenic therapy: microvessel density, what it does and doesn’t
tell us. J Natl Cancer Inst 94: 883–893
Kaelin Jr WG (2004) The von Hippel-Lindau tumor suppressor gene and
kidney cancer. Clin Cancer Res 10: 6290S–6295S
Konig B, Steinbach F, Janocha B, Drynda A, Stumm M, Philipp C, Allhoff
EP, Konig W (1999) The differential expression of proinflammatory
cytokines IL-6, IL-8 and TNF-alpha in renal cell carcinoma. Anticancer
Res 19: 1519–1524
Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble
JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E,
Roos G, Schmidt D, Srigley JR, Storkel S, van den Berg E, Zbar B (1997)
The Heidelberg classification of renal cell tumours. J Pathol 183: 131–133
Lindahl P, Johansson BR, Leveen P, Betsholtz C (1997) Pericyte loss
and microaneurysm formation in PDGF-B-deficient mice. Science 277:
242–245
Mandriota SJ, Pyke C, Di Sanza C, Quinodoz P, Pittet B, Pepper MS (2000)
Hypoxia-inducible angiopoietin-2 expression is mimicked by iodonium
compounds and occurs in the rat brain and skin in response to systemic
hypoxia and tissue ischemia. Am J Pathol 156: 2077–2089
Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM,
Wykoff CC, Maher ER, Harris AL, Ratcliffe PJ, Maxwell PH (2002) HIF
activation identifies early lesions in VHL kidneys: evidence for
site-specific tumor suppressor function in the nephron. Cancer Cell 1:
459–468
Nativ O, Sabo E, Reiss A, Wald M, Madjar S, Moskovitz B (1998) Clinical
significance of tumor angiogenesis in patients with localized renal cell
carcinoma. Urology 51: 693–696
Oh H, Takagi H, Suzuma K, Otani A, Matsumura M, Honda Y (1999)
Hypoxia and vascular endothelial growth factor selectively up-regulate
angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem
274: 15732–15739
Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han
SJ, Hawkins N, Rosenfeld R, Davy E, Graham K, Jacobsen F, Stevenson S,
Ho J, Chen Q, Hartmann T, Michaels M, Kelley M, Li L, Sitney K, Martin
F, Sun JR, Zhang N, Lu J, Estrada J, Kumar R, Coxon A, Kaufman S,
Pretorius J, Scully S, Cattley R, Payton M, Coats S, Nguyen L, Desilva B,
Ndifor A, Hayward I, Radinsky R, Boone T, Kendall R (2004)
Suppression of angiogenesis and tumor growth by selective inhibition
of angiopoietin-2. Cancer Cell 6: 507–516
Papapetropoulos A, Garcia-Cardena G, Dengler TJ, Maisonpierre PC,
Yancopoulos GD, Sessa WC (1999) Direct actions of angiopoietin-1 on
human endothelium: evidence for network stabilization, cell survival,
and interaction with other angiogenic growth factors. Lab Invest 79:
213–223
Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW,
Maxwell PH, Harris AL, Ratcliffe PJ (2005) Contrasting properties of
hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-
associated renal cell carcinoma. Mol Cell Biol 25: 5675–5686
Rioux-Leclercq N, Epstein JI, Bansard JY, Turlin B, Patard JJ, Manunta A,
Chan T, Ramee MP, Lobel B, Moulinoux JP (2001) Clinical significance of
cell proliferation, microvessel density, and CD44 adhesion molecule
expression in renal cell carcinoma. Hum Pathol 32: 1209–1215
Rosenberger C, Mandriota S, Jurgensen JS, Wiesener MS, Horstrup JH, Frei
U, Ratcliffe PJ, Maxwell PH, Bachmann S, Eckardt KU (2002) Expression
of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic
rat kidneys. J Am Soc Nephrol 13: 1721–1732
Ruoslahti E (2002) Specialization of tumour vasculature. Nat Rev Cancer 2:
83–90
Sabo E, Boltenko A, Sova Y, Stein A, Kleinhaus S, Resnick MB (2001)
Microscopic analysis and significance of vascular architectural complex-
ity in renal cell carcinoma. Clin Cancer Res 7: 533–537
Semenza GL (1999) Regulation of mammalian O2 homeostasis by hypoxia-
inducible factor 1. Annu Rev Cell Dev Biol 15: 551–578
Semenza GL (2000) Hypoxia, clonal selection, and the role of HIF-1 in
tumor progression. Crit Rev Biochem Mol Biol 35: 71–103
Shvarts O, Seligson D, Lam J, Shi T, Horvath S, Figlin R, Belldegrun A,
Pantuck AJ (2005) p53 is an independent predictor of tumor recurrence
and progression after nephrectomy in patients with localized renal cell
carcinoma. J Urol 173: 725–728
Thijssen VL, Brandwijk RJ, Dings RP, Griffioen AW (2004) Angiogenesis
gene expression profiling in xenograft models to study cellular
interactions. Exp Cell Res 299: 286–293
Van den Eynden GG, Van der Auwera I, Van Laere SJ, Colpaert CG, Turley
H, Harris AL, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA (2005)
Angiogenesis and hypoxia in lymph node metastases is predicted by the
angiogenesis and hypoxia in the primary tumour in patients with breast
cancer. Br J Cancer 93: 1128–1136
Wiesener MS, Munchenhagen PM, Berger I, Morgan NV, Roigas J,
Schwiertz A, Jurgensen JS, Gruber G, Maxwell PH, Loning SA, Frei U,
Maher ER, Grone HJ, Eckardt KU (2001) Constitutive activation of
hypoxia-inducible genes related to overexpression of hypoxia-inducible
factor-1alpha in clear cell renal carcinomas. Cancer Res 61: 5215–5222
Yao X, Qian CN, Zhang ZF, Tan MH, Kort EJ, Yang XJ, Resau JH, Teh BT
(2007) Two distinct types of blood vessels in clear cell renal cell
carcinoma have contrasting prognostic implications. Clin Cancer Res 13:
161–169
Yu JL, Rak JW, Carmeliet P, Nagy A, Kerbel RS, Coomber BL (2001)
Heterogeneous vascular dependence of tumor cell populations. Am J
Pathol 158: 1325–1334
Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS (2002) Effect of
p53 status on tumor response to antiangiogenic therapy. Science 295:
1526–1528
Angiogenesis in renal cell carcinoma
MM Baldewijns et al
1895
British Journal of Cancer (2007) 96(12), 1888–1895 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s